See more : Stanmore Resources Limited (SMR.AX) Income Statement Analysis – Financial Results
Complete financial analysis of HealthCare Global Enterprises Limited (HCG.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of HealthCare Global Enterprises Limited, a leading company in the Medical – Care Facilities industry within the Healthcare sector.
- Hong Kong Food Investment Holdings Limited (0060.HK) Income Statement Analysis – Financial Results
- Latin Resources Limited (LRSRF) Income Statement Analysis – Financial Results
- nms Holdings Corporation (2162.T) Income Statement Analysis – Financial Results
- Zhejiang Yasha Decoration Co.,Ltd (002375.SZ) Income Statement Analysis – Financial Results
- Kanpai Co., Ltd (1269.TWO) Income Statement Analysis – Financial Results
HealthCare Global Enterprises Limited (HCG.NS)
About HealthCare Global Enterprises Limited
HealthCare Global Enterprises Limited, together with its subsidiaries, provides healthcare services focusing on cancer. The company offers cancer diagnosis and treatment services through radiation therapy, medical oncology, and surgery; and fertility treatment services, as well as reproductive medicine services, including assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. It also operates four multi-specialty hospitals, including three under the HCG brand in Ahmedabad, Bhavnagar, and Rajkot in the state of Gujarat, as well as one under operations and management contract in Hubli in the state of Karnataka that primarily provide cardiology, neurology, orthopedics, gastroenterology, urology, internal medicine, and pulmonary and critical care. In addition, the company offers medical diagnostic services, including scientific testing and consultancy services in the pharmaceutical and medical sector. As of March 31, 2021, it operated 23 cancer centers, including 1 center of excellence in Bengaluru, 2 freestanding diagnostic centers, and 1 day care chemotherapy center across India, as well as 1 cancer center in Africa. The company was founded in 1989 and is based in Bengaluru, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.90B | 16.91B | 13.83B | 10.04B | 10.81B | 9.61B | 8.18B | 7.00B | 5.82B | 5.19B | 4.51B | 3.38B |
| Cost of Revenue | 9.10B | 7.80B | 6.82B | 5.00B | 5.23B | 4.67B | 3.81B | 3.40B | 1.50B | 1.46B | 2.26B | 1.69B |
| Gross Profit | 9.80B | 9.11B | 7.01B | 5.04B | 5.57B | 4.94B | 4.37B | 3.60B | 4.32B | 3.73B | 2.26B | 1.70B |
| Gross Profit Ratio | 51.85% | 53.87% | 50.69% | 50.21% | 51.56% | 51.39% | 53.46% | 51.39% | 74.30% | 71.88% | 50.00% | 50.13% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 678.71M | 674.29M | 423.84M | 276.25M | 249.86M | 259.12M | 251.50M | 128.72M | 125.37M | 114.38M | 155.80M | 92.46M |
| Selling & Marketing | 401.24M | 336.50M | 181.06M | 135.74M | 193.26M | 121.93M | 100.61M | 105.07M | 95.57M | 139.45M | 98.42M | 67.27M |
| SG&A | 1.08B | 1.01B | 604.90M | 411.99M | 443.12M | 381.05M | 352.11M | 233.79M | 125.37M | 114.38M | 254.22M | 159.73M |
| Other Expenses | 8.72B | 131.80M | 4.95M | 11.88M | 11.38M | 30.33M | 33.30M | 9.60M | 11.53M | 11.97M | 0.00 | 0.00 |
| Operating Expenses | 9.80B | 7.76B | 6.24B | 5.37B | 5.31B | 4.54B | 3.80B | 3.12B | 3.87B | 3.36B | 2.24B | 1.53B |
| Cost & Expenses | 18.90B | 15.56B | 13.06B | 10.37B | 10.54B | 9.21B | 7.61B | 6.52B | 5.37B | 4.82B | 4.50B | 3.22B |
| Interest Income | 50.36M | 118.10M | 115.61M | 156.11M | 42.41M | 35.35M | 88.08M | 42.73M | 18.44M | 31.47M | 0.00 | 267.49M |
| Interest Expense | 994.51M | 1.04B | 838.87M | 1.10B | 1.24B | 510.66M | 370.01M | 200.11M | 320.91M | 316.79M | 284.33M | 0.00 |
| Depreciation & Amortization | 1.74B | 1.63B | 1.58B | 1.59B | 1.48B | 850.85M | 714.60M | 568.25M | 449.93M | 399.26M | 361.76M | 295.74M |
| EBITDA | 3.50B | 3.06B | 3.41B | 474.52M | 1.70B | 1.09B | 1.41B | 1.15B | 809.44M | 746.19M | 389.55M | 486.07M |
| EBITDA Ratio | 18.54% | 18.44% | 16.51% | 12.07% | 14.42% | 10.67% | 16.43% | 15.63% | 15.19% | 15.26% | 8.63% | 13.78% |
| Operating Income | 92.80M | 1.36B | 795.46M | -333.74M | 229.47M | 396.09M | 574.12M | 482.30M | 454.54M | 370.57M | 27.79M | 170.57M |
| Operating Income Ratio | 0.49% | 8.01% | 5.75% | -3.32% | 2.12% | 4.12% | 7.02% | 6.89% | 7.81% | 7.13% | 0.62% | 5.04% |
| Total Other Income/Expenses | 584.49M | 508.87M | 103.58M | -1.98B | -1.46B | -735.66M | -302.36M | -133.87M | -406.59M | -340.43M | -271.29M | -272.02M |
| Income Before Tax | 677.29M | 448.70M | 877.72M | -2.29B | -1.19B | -333.75M | 271.76M | 348.43M | 50.02M | 30.14M | -266.52M | -101.45M |
| Income Before Tax Ratio | 3.58% | 2.65% | 6.35% | -22.77% | -11.04% | -3.47% | 3.32% | 4.98% | 0.86% | 0.58% | -5.91% | -3.00% |
| Income Tax Expense | 263.95M | 272.50M | 488.47M | -75.61M | 61.89M | -25.00M | 102.38M | 118.00M | -4.32M | -16.83M | 53.52M | 7.14M |
| Net Income | 481.55M | 293.40M | 537.33M | -1.93B | -1.07B | -247.97M | 205.23M | 221.73M | 12.21M | 8.34M | -355.53M | -105.14M |
| Net Income Ratio | 2.55% | 1.73% | 3.88% | -19.27% | -9.87% | -2.58% | 2.51% | 3.17% | 0.21% | 0.16% | -7.88% | -3.11% |
| EPS | 3.46 | 2.11 | 4.14 | -17.02 | -12.05 | -2.82 | 2.39 | 2.69 | -2.43 | 0.12 | -5.18 | -1.74 |
| EPS Diluted | 3.43 | 2.10 | 3.97 | -17.02 | -12.05 | -2.81 | 2.38 | 2.69 | -2.43 | 0.11 | -5.18 | -1.74 |
| Weighted Avg Shares Out | 139.13M | 139.07M | 129.71M | 113.65M | 88.55M | 87.91M | 86.05M | 85.16M | 72.87M | 69.95M | 68.64M | 60.36M |
| Weighted Avg Shares Out (Dil) | 140.41M | 139.71M | 135.18M | 113.65M | 88.55M | 88.10M | 86.20M | 85.17M | 72.87M | 73.30M | 68.68M | 60.36M |
Source: https://incomestatements.info
Category: Stock Reports